the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions. (2) …
Rindopepimut is Celldex' leading drug candidate in Phase 3 trials for the ... Sales growth has stalled for the last five quarters at around $80 million, and the stock hasn't fared well either.
Celldex Therapeutics, Inc. CLDX announced the initiation of a phase II study on its human monoclonal antibody, CDX-3379 in patients with advanced head and neck squamous cell carcinoma ("HNSCC"). With no approved products in its …
A late-stage study for a brain cancer vaccine has been discontinued, Celldex Therapeutics Inc. announced Monday. The drug manufacturing company said the results from a preplanned independent analysis found that the vaccine, Rintega, …